Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267104 | 0.81 | SMN1; SMN2 (0.49) | HDAC6GPR139POLBALK | |
| SCHEMBL5273044 | 0.80 | POLB (0.41) | HDAC6GPR139POLBALKMC4R | |
| SCHEMBL5269274 | 0.80 | ALDH1A1 (0.40) | GPR139RAPGEF4POLBSLC6A2 | |
| SCHEMBL5266896 | 0.77 | RAPGEF4 (0.34) | RAPGEF4 | |
| SCHEMBL13267554 | 0.76 | MC4R (0.41) | HDAC6GPR139POLBALKMC4R | |
| SCHEMBL5269254 | 0.75 | ADRB2 (0.42) | RAPGEF4POLB | |
| SCHEMBL5273020 | 0.73 | RAPGEF4 (0.35) | RAPGEF4 | |
| SCHEMBL5270038 | 0.73 | KMT2A (0.47) | HDAC6POLB | |
| SCHEMBL5274435 | 0.73 | RAPGEF4 (0.42) | GPR139RAPGEF4FFAR4 | |
| SCHEMBL5273175 | 0.73 | RAB9A (0.44) | RAPGEF4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074539-B1 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL CO (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-6894190-B2 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-17 | — | — | US | disclosed |
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6653507-B2 | Useful intermediate compound of pharmaceuticals for urinary incontinence | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-10-03 | — | — | US | disclosed |
| US-6403832-B1 | MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1074539-A2 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, CYP8B1, CYP11B2 | HDAC6 3271/4885GPR139 2758/4885RAPGEF4 1419/4885 |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, ALDH7A1, ALDH18A1 | HDAC6 1655/4885GPR139 1886/4885RAPGEF4 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.